González MAE

Idioma: Español
Referencias bibliográficas: 28
Paginas: 1-14
Archivo PDF: 177.50 Kb.

RESUMEN

El reconocimiento inicial de la disfunción cardíaca ocasionada por estrategias terapéuticas aplicadas contra el cáncer fue realizado en la sexta década del siglo XX. La Cardiooncología es una nueva disciplina horizontal dirigida a la identificación de los pacientes en riesgo elevado para el desarrollo de toxicidad cardíaca. El eficaz desempeño inherente a la Cardiooncología pediátrica radica en la adecuada selección del medio diagnóstico capaz de identificar y evaluar los indicios de cardiotoxicidad mediante la detección de cambios precoces en la funcionalidad del miocardio tras la aplicación de terapias antitumorales y, sobre todo, la predicción a largo plazo de estos eventos en niños sobrevivientes de cáncer. La cardiotoxicidad secundaria a la terapéutica aplicada sobre estos pacientes es un problema de salud latente en nuestro país que precisa la adopción de medidas organizativas concebidas para su enfrentamiento. Se persigue contribuir a la estructuración de la atención integral correspondiente al niño con cáncer y afectado por cardiotoxicidad en Cuba.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sheng C, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, et al. 21 st. century Cardio - Oncology. Identifying cardiac safety signals in the era of personalized medicine. JACC: Basic to translational science. 2016;1(5):386-98.

2. Haddy N, Diallo S, El-Fayech C. Cardiac diseases following childhood cancer treatment cohort study. Circulation. 2016;133:31-8.

3. Xinqiang H, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. Npj Precision Oncology. 2017;31:1-11.

4. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: Cardio – Oncology. Mayo Clinic Proceedings. 2014;89:1287-06.

5. Cardinale D, Colombo A, Bacchiani G. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131:1981-8.

6. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero LA, García Sanz R, Mazón Ramos P. Cardio – Onco – Hematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol. 2017; 70:474- 86.

7. Barac A, Murtagh G, Carver JR. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015; 65:2739- 46.

8. Planas JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from American Society of Echocardiography and the European Association of Cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063-93.

9. Armstrong G, Joshi V, Ness K. Comprehensive echocardiographic detection of treatment related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015; 65:2511-22.

10. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W; Cardiovascular disease task force of the Children’s Oncology Group. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008;121:e387- 96.

11. Spallarossa P, Maurea N, Cadedduc C. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med. 2016; 17:S84-S92.

12. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639- 42.

13. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016; 66:309-25.

14. Wang L, Tan TC, Halpern EF. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol. 2015;116:442 – 6.

15. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104-14.

16. Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA. Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med. 1997;102:252-8.

17. Adler Y, Charron P, Imazio M. European Society of Cardiology (ESC). Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases. Eur Heart J. 2015; 36:2921-64.

18. Casey DJ, Kim AY, Olszewski AJ. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. Am J Hematol. 2012; 87:521-4.

19. Gahler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie. 2003;26:348-50.

20. Terpstra W, De Maat CE. Pericardial fibrosis following busulfan treatment. Neth J Med. 1989:35:249-52.

21. López-Fernández T, Thavendiranathan P. Emerging cardiac image modalities for early detection of cardiotoxicity derived for anticancer therapies. Rev Esp Cardiol. 2017;70:487- 95.

22. Virani SA, Dent S, Brezden – Masley C. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016; 2:831- 41.

23. Ramjaun A, Al Duhaiby E, Ahmed S, Wang L, Yu E. Echocardiographic detection of cardiac dysfunction in childhood cancer survivors: How long is screening required ? Pediatr Blood Cancer. 2015;62:2197-203.

24. Nolan M, Plana JC, Thavendiranathan P, Thomas JD, Badano LP, Voigt JU. Costeffectiveness of strain-targeted cardioprotection for prevention of chemotherapy induced cardiotoxicity. Int J Cardiol. 2016;212:336-45.

25. Stefani L, Pedrizzetti G, Galanti G. Clinical Application of 2D speckle tracking strain for assessing cardiotoxicity in Oncology. J Funct Morphol Kinesiol. 2016;1:343-54.

26. Henri C, Heinonen T, Tardif JC. The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy. Biomark Cancer. 2016;8:39-45.

27. Ponikowski P, Voors A, Anker SD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-200.

28. Abbasi SA, Ertel A, Shah RV, Dandekar V, Chung J, Bhat G. Impact of cardiovascular magnetic resonance on management and clinical decision making in heart failure patients. J Cardiovasc Magn Reson. 2013;15:15-89.